Advertisement

Topics

Pfizer-led consortium begins trial of metastatic breast cancer treatment palbociclib

02:07 EDT 23 Aug 2017 | Pharmaceutical Business Review

Pfizer, along with Alliance Foundation Trials (AFT) and six other international cancer research groups, has commenced a phase 3 clinical study to assess palbociclib (Ibrance) for the treatment of patients with metastatic breast cancer.

Original Article: Pfizer-led consortium begins trial of metastatic breast cancer treatment palbociclib

NEXT ARTICLE

More From BioPortfolio on "Pfizer-led consortium begins trial of metastatic breast cancer treatment palbociclib"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...